NEW YORK, September 24, 2015 /PRNewswire/ --
ACI Association has initiated research coverage on the following equities: Cerus Corporation (NASDAQ: CERS), Cross Country Healthcare, Inc. (NASDAQ: CCRN), Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), Antares Pharma, Inc. (NASDAQ: ATRS), CEPHEID (NASDAQ: CPHD). On Wednesday, September 23, 2015, Nasdaq ended at 4752.74, down 0.08%, Dow Jones declined 0.31%, to finish the day at 16279.89, and the S&P closed at 1938.76, down 0.20%. Register for your complimentary reports at the links given below.
--
Cerus Corp
--
Cerus Corp's stock edged lower by 2.42% to close Wednesday's session at USD 5.24. The company's shares oscillated between USD 5.14 and USD 5.36. The stock recorded a trading volume of 0.77 million shares, which was below its 50-day daily average volume of 0.86 million shares and below its 52-week average volume of 1.13 million shares. Over the last three days, Cerus Corp's shares have declined by 9.50% and in the past one week it has moved down 5.92%. Furthermore, over the last three months, the stock has lost 2.60% while in the past six months, the shares have picked up 30.35%. The stock is at a price to book ratio of 4.60. The historical PB ratio is near to 12.08. Additionally, the stock is trading at a price to sales ratio of 13.93. Sign up and read the free notes on CERS at: http://www.aciassociation.com/CERS.pdf
--
Cross Country Healthcare Inc
--
The stock of Cross Country Healthcare Inc gained 3.66% to close Wednesday's session at USD 15.85. The shares of the company moved in the range of USD 15.40 and USD 16.20. A trading volume of 0.75 million shares was recorded, which was greater than its 150-day daily average volume of 0.24 million shares and above its 52-week average volume of 0.23 million shares. Over the last five days, Cross Country Healthcare Inc's shares have advanced 14.11% and in the past one month, it has gained a momentum of 9.99%. The company has returned 26.19% in the last three months, on a compounded total return basis. The stock is at a price to book ratio of 3.75. The historical PB ratio is near to 3.01. Further, the stock is trading at a price to cash flow ratio of 35.25 and price to sales ratio of 0.68. Register for free on ACI Association and access the latest research on CCRN at: http://www.aciassociation.com/CCRN.pdf
--
Alder Biopharmaceuticals Inc
--
Alder Biopharmaceuticals Inc's stock decreased by 1.75% to close Wednesday's session at USD 37.67. The company's shares fluctuated in the range of USD 36.97 and USD 38.48. A total of 0.67 million shares exchanged hands, which surpassed its 50-day daily average volume of 0.60 million shares and was above its 52-week average volume of 0.48 million shares. Over the last three days Alder Biopharmaceuticals Inc's shares have declined by 11.92% and in the past one week it has moved down 7.49%. Furthermore, over the last three months, the stock has lost 24.39% and in the past six months, the shares have picked up 35.70%. The company has returned 29.18% in the last half year, on a compounded total return basis. The complete research on ALDR is available for free at:
http://www.aciassociation.com/ALDR.pdf
--
Antares Pharma Inc
--
Antares Pharma Inc's stock added 1.09% to close Wednesday's session at USD 1.85. The company's shares oscillated between USD 1.80 and USD 1.90. The stock recorded a trading volume of 0.66 million shares, which was below its 52-week average volume of 0.80 million shares. Over the last five days, Antares Pharma Inc's shares have declined by 1.07% while in the past one month, it has gained a momentum of 2.21%. In addition, over the last three months, the stock has gained 7.37% and year to date, the shares have shed 28.02%. The stock is at a price to book ratio of 11.47. Additionally, the stock is trading at a price to sales ratio of 18.69. Free in-depth research on ATRS is available at: http://www.aciassociation.com/ATRS.pdf
--
CEPHEID
--
CEPHEID's stock declined 0.45% to close Wednesday's session at USD 50.93. The share price vacillated between USD 50.27 and USD 52.10. The stock recorded a trading volume of 0.65 million shares, which was below its 50-day daily average volume of 0.81 million shares and above its 52-week average volume of 0.59 million shares. Over the last three days CEPHEID's shares have declined by 2.02% and in the past one week it has moved down 3.51%. Moreover, in the last six months, the stock has lost 4.46% and year to date, the shares have shed 5.93%. The stock is at a price to book ratio of 9.80. The historical PB ratio is near to 10.84. Additionally, the stock is trading at a price to cash flow ratio of 125.01 and price to sales ratio of 7.17. The complimentary notes on CPHD can be downloaded in PDF format at: http://www.aciassociation.com/CPHD.pdf
--
About ACI Association:
Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein. The information in this release has been sourced from a third party data base.
NO WARRANTY
ACI Association, the Author, the Reviewer and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.aciassociation.com/.
RESTRICTIONS
ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE www.aciassociation.com
